The glucagon receptor and the adenylyl cyclase system of human liver membranes were studied in six non-obese and six obese subjects who had elevated insulin and plasma glucagon levels. Analysis of specific glucagon binding by the method of Scatchard demonstrated a linear (monocomponent) plot with a dissociation constant of 2-3 nM, and the binding at low hormone concentrations was sensitive to guanosine triphosphate (GTP). The molecular weight of the glucagon receptor was 63,000 D as determined by an affinity labeling procedure and sodium dodecyl sulfate gel electrophoresis. Affinity labeling of this structure was specific for glucagon and inhibited by GTP. Glucagon stimulated the production of cyclic adenosine monophosphate (cAMP) by human membranes with halfmaximal activation elicited by 6 nM hormone. The human cyclase system required GTP to facilitate an optimal glucagon response. NaF (10 mM) also activated the cyclase system and produced the same magnitude of response as maximum glucagon activation. A comparison of the liver adenylyl cyclase system of non-obese and obese subjects was made using glucagon (5 nM and 1 microM) and NaF (10 mM). No significant differences in cAMP production were noted between the two groups, regardless of the agent used to activate the enzyme. These findings agree with the glucagon binding studies that showed similar amounts of binding activity in the membranes from the two groups. 
Introduction
Glucagon is an important contributor to the regulation of hepatic fuel production (1) . Although the liver is a primary site of glucagon action (2) , and several studies in man have demonstrated significant hepatic extraction of the hormone (3) (4) (5) , very little direct information is available regarding the interaction of glucagon with the human glucagon receptor, the structure of this receptor, or the characteristics for the hormone activation of the adenylyl cyclase system. Two reports have shown the ability of glucagon to stimulate cyclic adenosine triphosphate (cAMP)' production by human liver membranes (6, 7) , but studies of the glucagon receptor were not described.
Understanding these basic features of glucagon action is important, particularly since in certain diseases like diabetes, glucagon has been implicated in contributing to the overall pathophysiology (8) . Obesity is another abnormality in which recent findings suggest an oversecretion of glucagon (9) . It is possible that the oversecretion produces changes in glucagon receptor number and/or its ability to activate the adenylyl cyclase system. For example, in animal studies and in vitro experiments, elevations in glucagon reduce the number of glucagon receptors and decrease glucagon action (10, 12) . Unfortunately, studies of glucagon action in human obesity have given ambiguous results, as have the studies of animal models for obesity ( 13) .
In the present study, we examined the interaction of glucagon with the glucagon receptor of human liver membranes, the molecular weight of the glucagon receptor, and the ability of the hormone to stimulate adenylyl cyclase. In addition, studies of the effect of this hormone on adenylyl cyclase activity were conducted in liver membranes from obese subjects, to directly evaluate in this disorder an early step in glucagon action.
Methods
Materials. Carrier-free '251I-Na, [3H] cAMP, and [a-32P]ATP were purchased from Amersham Corp., Arlington Heights, IL. Guanosine triphosphate (GTP), ATP, glucagon, creatine phosphate, creatine phosphokinase (type I), myokinase (grade III), Dowex-50 (hydrogen form), and alumina (chromatographic, neutral) were supplied by Sigma Chemical Co., St. Louis, MO.
Human subjects. Six non-obese and six obese subjects were studied (see Table I for clinical data). The non-obese subjects were admitted to the Surgical Department (Karolinska Institute, Stockholm, Sweden) for elective cholecystectomy; otherwise, they were healthy. The obese subjects were admitted for gastric operations for obesity. The body weight of all the subjects was constant during the 3-mo period before admittance, and none was receiving any drugs that affect liver or carbohydrate metabolism. The subjects were maintained as inpatients on a weight-maintaining diet (45% carbohydrate, 20% protein, and 35% fat) for 3 d before surgery. After an overnight fast, general anesthesia was induced with a short-acting barbiturate and maintained by phenanyl and a nitrous oxide-oxygen mixture. During surgery, a liver biopsy (1 g) was taken from the left lobe of the liver. The biopsy was immediately placed in ice-cold buffer and taken to the laboratory for the isolation of liver membranes. This study was approved by the Ethical Committee of the Karolinska Institute. Informed consents were obtained from the subjects after they were given a detailed description of the study.
Preparation ofliver membranes. The liver biopsy was homogenized in 50 ml of a 1-mM NaHCO3 buffer, pH 7.5, that contained 0.5 mM CaC12 (14) . The homogenate was subjected to centrifugation at 10,000 g for 20 min, and the membranes were washed in 0.25 M sucrose, 10 mM Tris buffer, pH 7.4. The membranes were resuspended in this buffer, frozen at -80'C, and shipped to Rochester, NY for further analysis. Protein content in the membrane preparation was determined as previously described (15) .
Rat liver plasma membranes were prepared by the two-phase polymer method of Lesko et al. (14) .
Glucagon binding studies. Glucagon was radiolabeled with 125I-Na to a specific activity of 0.8-1.0 Ci/Mmol by the chloramine-T method (16) . Liver membranes (10-20 ug Photoaffinity labeling and sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis of the glucagon receptor. Liver membranes (1.0 mg protein) were incubated with '25I-glucagon and other agents, as indicated in Results, in 1 ml of the buffer used in studies of glucagon binding. After a 20-min incubation at 21 C, the membranes were rapidly chilled to 4°C and pelleted by a 3-min centrifugation step in a microfuge (Beckman Instruments, Inc., Fullerton, CA). The membrane pellet was washed twice by resuspension in I ml of an ice-cold 20-mM sodium phosphate buffer, pH 7.4, followed by microfuge centrifugation. After the second wash, the pellet was resuspended in the dark in I ml of the phosphate buffer that contained 20 M1 of a solution of 6.5 mg of N-hydroxysuccimidyl-4-azidobenzoate in I ml of dimethyl sulfoxide (21). The membranes were incubated in the dark at 4°C for 10 min. The reaction was terminated by the addition of 20 Ml of a 2-M Tris-HCI solution, pH 7.4. The membrane suspension was placed in a small petri dish (35-mm diam) on ice. The dish was positioned 15 cm under a sunlamp (275 W and 110-125 V; General Electric Co.) and exposed to light for 10 min with constant shaking. The membranes were pelleted by microfuge centrifugation and dissolved in 2% SDS, 40 mM Tris-HCI buffer, pH 6.8, that contained 5% 2-mercaptoethanol. After being heated at 100°C for 5 min, the samples were subjected to polyacrylamide gel electrophoresis using a 5-12% gradient resolving gel as described by Laemmli (22). After electrophoresis, the gels were fixed in 10% trichloroacetic acid, stained with Coomassie Blue R-250, destained, and dried. The gels were exposed to preflashed film (XOmatic; Eastman Kodak Co., Rochester, NY) using intensifying screens (X-Omatic; Eastman Kodak Co. branes. This difference may be due in part to the use of a highly purified preparation of rat liver plasma membranes, whereas the human preparation is not as enriched in this fraction. It is also likely that the difference in the ratio of tcteristics of the two specific vs. total glucagon binding in the two membranẽ 'eight of the subjects preparations arises from the difference in purity.
iat of the non-obese
It was not possible to cany out complete glucagon binding levels in the obese studies on all of the human membrane preparations because found in the normal of the limited amount of material. Instead, the ability of the ihanced fasting blood membrane fractions from six non-obese and five obese subjects )wever, on two other to specifically bind 3 nM 1251-glucagon was compared. The we, his blood glucose mean for glucagon binding by the non-obese preparations was raining subjects had . In these studies we also examined the effect mbranes was 90% of of theophylline (3 mM) and found that it did not alter the rate of cAMP production (data not shown). Thus, phospho--agon binding to liver diesterase did not destroy a fraction of the cAMP formed is illustrated, the plot during these assays.
quite similar to the
The effect of GTP formation on cAMP was studied (Table   II) , and as indicated, this nucleotide is required to obtain the full stimulation of the cyclase system in the human membranes.
In the absence of GTP, glucagon elicited only a 50% stimulation compared with the stimulation found in the presence of the nucleotide. Basal cAMP formation was also affected, being reduced to the lower limit of our ability to accurately measure R a t cAMP formation. Furthermore, GTP at a concentration of 1 MuM was sufficient to allow glucagon to maximally activate the cyclase system. Higher nucleotide concentrations did not significantly change basal or glucagon-stimulated cAMP production from the rates found with 1 MM GTP. GTP also affected glucagon binding by human liver membranes, as reported for membranes from rat liver (19 the glucagon receptor, and enhances glucagon-stimulated activation of human adenylyl cyclase activity. A comparison of the glucagon dose-response relationship between human and rat liver membranes is shown in Fig. 2 . Maximum activation of the adenylyl cyclase system is produced by 0.33 ;M glucagon in both membrane preparations. Halfmaximal activation in human membranes was produced by a glucagon concentration of -6 nM, compared with a concentration of 8 nM for rat liver membranes. Note that the amount of protein and the incubation period used in these experiments differed for the two membrane preparations. When standardized to the same membrane concentration and incubation period, basal cAMP formation by human membranes is approximately one-half that found in the rat preparation, and maximal glucagon-stimulated activity is one-third. Again, these quantitative differences between the two membrane preparations are likely due in part to different degrees of enrichment in plasma membranes. As subsequently demonstrated (see Fig. 3 ), the response of human membranes to 10 mM NaF is quite similar to that produced by maximal glucagon stimulation. This relationship is well established in highly enriched preparations of rat liver plasma membranes (25), which suggests that the lack of purity of the human preparations does not alter their ability to respond to the hormone. Fig. 3 compares the ability of membranes from non-obese and obese subjects to respond to glucagon and NaF. Two glucagon concentrations were used; one that produces approximately half-maximal stimulation, and another that maximally activates the cyclase system. NaF was included in the study to provide an independent estimate of cyclase content and a separate parameter other than membrane protein to standardize glucagon stimulation. The results indicate similar basal adenylyl cyclase activity between both groups, with no significant dif- ferences in cAMP formation with either concentration of glucagon or with NaF stimulation. Thus, the membranes isolated from the obese subjects have a normal response to glucagon, a finding that agrees with normal '25I-glucagon binding.
Studies of the structure of the human glucagon receptor. Because of the large amount of membranes required by the structural studies, membranes from four normal subjects were pooled for these studies. Fig. 4 shows an autoradiogram of a polyacrylamide gel after the affinity labeling procedure described in Methods was carried out in human and rat liver membranes.
Both membranes contain several structures that are labeled with '251-glucagon by the photoaffinity labeling technique.
However, only one structure in each membrane preparation is specifically labeled with '251-glucagon, i.e., one whose labeling is markedly reduced by the presence of 1 gM native glucagon.
The molecular weight of this structure in rat liver membranes is -58,000, whereas in human membranes, the affinity labeled component is slightly larger, having a molecular weight of 63,000.
To further characterize the specificity of this binding component for glucagon and to compare it with the established features of the glucagon receptor, studies using native insulin, GTP, and different concentrations of native glucagon were conducted (Fig. 5) . As 
Discussion
These findings demonstrate a glucagon receptor and a responsive adenylyl cyclase system in human liver membranes that are quite similar to the well-characterized system in rat liver membranes (17, 19, 25) . Similarities are apparent in the glucagon binding characteristics between human and rat receptors, and both structures also have similar molecular weights. The Mr value of 63,000 for the human receptor is only slightly larger than the Mr 58,000 found in the rat liver membranes. These values are much larger than the 23,000 Mr originally reported by Bregman and Levy (26) ; however, they agree in general with the more recent reports of the size of the rat glucagon receptor, which range from 52,000 to 70,000 Mr (21, 27, 28).
The adenylyl cyclase system of human membranes also had a similar sensitivity to glucagon stimulation as rat liver membranes. The median effective dose value for stimulation by glucagon was 6 nM, and GTP was required for glucagon to fully activate the cyclase system. This GTP effect differs from the results described by Pecker et al. (7), who stated that the nucleotide did not affect the ability of glucagon to stimulate cAMP production. since our data clearly show an effect of GTP both on the glucagon receptor binding activity and its ability to activate the adenylyl cyclase system. The ability of human liver membranes from obese subjects to respond to glucagon was examined because recent findings indicate the presence of hyperglucagonemia in this disorder (9) . Although other work has given conflicting results (reviewed in 13), the careful studies by Starke et al. (9) clearly demonstrate elevated pancreatic glucagon in obese subjects, including those who were glucose tolerant or intolerant. Our obese subjects also showed evidence of increased secretion. We measured plasma glucagon with a sensitive and specific radioimmunological method (23, 24) and observed almost a 100% increase in the fasting glucagon level in obese subjects compared with non-obese subjects.
The presence of hyperglucagonemia in obesity raises the possibility that alterations exist in the number of glucagon receptors and glucagon action in much the same manner that hyperinsulinemia is associated with insulin resistance and loss of insulin receptors (29) . Our findings show, however, that the membranes from obese subjects are as glucagon-responsive as those from normal weight subjects, regardless of the basis for expressing the glucagon effect, i.e., per milligram of protein, or the ability of NaF to stimulate cAMP production. These findings, along with the similar amount of glucagon binding activity in the two groups, indicate an adequate population of glucagon receptors that are appropriately coupled to the adenylyl cyclase system in obesity. Thus, unlike in vitro studies of hepatocytes, in which high concentrations of glucagon cause "down-regulation" of the glucagon receptor and a loss of response to the hormone (10), the moderate hyperglucagonemia found in obesity is not sufficient to elicit changes in receptor number or alterations in hormone action. It is also possible that the mild degree of hyperglucagonemia and the pulsatile delivery of the hormone that occurs in normal and obese subjects (30) helps prevent receptor loss and the development of glucagon resistance.
In summary, human liver membranes contain a glucagon receptor of Mr 63,000 and an adenylyl cyclase system that corresponds closely to the well-studied system in rat liver membranes. Furthermore, the hyperglucagonemia that develops in obesity does not alter the ability of this system to respond to glucagon. These findings do not eliminate the possibility of alterations at sites beyond the cyclase system, e.g., elevated phosphodiesterase activity (31), but they show that in obesity the initial steps in hepatic glucagon action are intact.
